HTG Introduces HTG EdgeSeq Reveal RUO Oncology Applications

TUCSON, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Reveal RUO oncology applications, which are expected to be commercially available globally in late August with the release of HTG EdgeSeq Reveal version 3.0.

In January 2019, HTG launched HTG EdgeSeq Reveal, a web-based biostatistical analysis software suite, which is designed to allow customers to streamline their analysis of samples processed with HTG’s RUO profiling assays and accelerate their critical research. With the release of version 3.0, HTG introduces the first RUO oncology applications specifically built upon the HTG EdgeSeq Precision Immuno-Oncology Panel (PIP), including three complimentary signatures aimed at understanding the immune response (inflammation) and biology of the tumor microenvironment. These initial RUO oncology applications include:

• HTG EdgeSeq Reveal Immune Signature
• HTG EdgeSeq Reveal Stroma Signature
• HTG EdgeSeq Reveal Tumor Microenvironment Signature

“Our purpose-built signatures are intended to leverage the gene expression data from our PIP assay and enable researchers to better understand the tumor microenvironment including tumor inflammation (Hot vs. Cold) and stromal response to a tumor,” said Marian Navratil, Vice President, Research and Development. “The approach for these signatures is based upon the xCell algorithm, one of the most well-documented gene signature-based methods that combines sophisticated gene enrichment and deconvolution approaches. These signatures were designed to be tissue-agnostic, having been developed from over 1,000 formalin-fixed, paraffin-embedded (FFPE) tissue samples across multiple different tumor types and orthogonally compared to multiple commonly used inflammation immunohistochemistry markers in an independent cohort.”

Byron Lawson, Senior Vice President and Chief Commercial Offer, added, “Characterization of the immune response in the tumor microenvironment continues to be an important step in developing biomarker strategies to understand the body’s immune response in relation to cancer biology and potential response to mono and combination therapies. Expanding the applications available through our HTG EdgeSeq Reveal software suite, we believe customers will have the ability to potentially accelerate their discovery, support translational applications, and determine potential biomarkers for development of companion diagnostics. These applications are the first of many we plan to commercialize in both Oncology and Immunology.”